info@njbio.com
Request a Quote
675 US Highway 1, Suite B129, North Brunswick, NJ 08902
Request a Quote
Selection of a proper payload-linker (also known as drug-linker, toxin-linker or linker-payload) is essential. At NJ Bio, we add value by not just offering high-quality payload-linkers, but also by helping in the selection of the most appropriate one based on the biology of the target. Our experts can help identify a screening cascade to move from early discovery to finding a clinical candidate. Our extensive chemistry and ADC experience allows us to mix and match a variety of linker and payload technologies to maximize the clinical properties of the resulting bioconjugate. Being an advisor and partner is an important part of the work we do. NJ Bio can also provide scale-up and development of payload-linkers to help accelerate the synthesis of your clinical candidate. Having a partner like NJ Bio with deep bioconjugation and chemistry know-how can add tremendous value in the selection and development of bioconjugate therapeutics.
Discovery Payload-Linker Services
Validated
payload-linkers
What types of payload and linkers are best?
Custom
payload-linkers
Application: Fine-tuning DAR, PK, aggregation
Novel
payload-linkers
Unique chemical space and new technologies
NJ Bio’s Payload-Linker Design Process
We can help at different stages of the R&D process and select the fastest pathway to developing a bioconjugate clinical candidate. We supply validated as well as custom and novel linker-payloads. We can support chemical scale-up and development of linker-payloads. NJ Bio can create value when new, custom and challenging chemistry is required. Contact us to see how we can bring value to your program(s).
Value through Speed, Ownership, and Results
Validated Payload-Linkers
Custom Payload-Linkers
Novel Payload-Linkers
Scale-Up
Development Support
cGMP Suites
We are working on expanding our services to manufacture material for IND-enabling studies and phase 1 and 2 clinical trials. These cGMP suites are scheduled to be operational in 3Q 2021.
Click here for review articles for antibody drug conjugates